Targeted Triple Inhibition of KRAS, EGFR, and STAT3 in Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, characterized by near-universal activating mutations in KRAS and frequent co-mutations in TP53, CDKN2A, and SMAD4. Despite advances in targeted therapy, single-agent inhibition of KRAS has demonstrated limited durability due to rapid emergence of adaptive resistance mechanisms.
This lecture reviews a recent preclinical study demonstrating that simultaneous pharmacologic inhibition of three critical signaling nodes—KRAS, EGFR, and STAT3—induces complete and durable tumor regression in murine models of PDAC, including orthotopic and patient-derived xenograft (PDX) systems.
By the end of this lecture, participants will be able to:
* Explain why KRAS-mutant PDAC demonstrates rapid resistance to single-agent KRAS inhibition.
* Describe the role of EGFR and STAT3 in adaptive signaling escape.
* Discuss this study curing PDX in mice by blocking STAT3 protein clusters.
* Evaluate the strengths and limitations of preclinical combination therapy studies.
By the end of this lecture, participants will be able to:
* Explain why KRAS-mutant PDAC demonstrates rapid resistance to single-agent KRAS inhibition.
* Describe the role of EGFR and STAT3 in adaptive signaling escape.
* Discuss this study curing PDX in mice by blocking STAT3 protein clusters.
* Evaluate the strengths and limitations of preclinical combination therapy studies.
Write A New Comment
0 Comments